Holen Sie sich die Stockscreener-App
1.77
15.71%
-0.33
Handel nachbörslich:
1.82
0.05
+2.82%
Schlusskurs vom Vortag:
$2.10
Offen:
$2.1
24-Stunden-Volumen:
1.28M
Relative Volume:
2.34
Marktkapitalisierung:
$186.46M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-4.6727
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-11.06%
1M Leistung:
-23.71%
6M Leistung:
-23.04%
1J Leistung:
-32.44%
1-Tages-Spanne:
$1.74
$2.12
1-Wochen-Bereich:
$1.74
$2.275
52-Wochen-Spanne:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.77 | 221.22M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com India
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Can ProQR Therapeutics N.V. stock sustain market leadershipEarnings Date Calendar & Fast Profit Trading Strategies - Bollywood Helpline
How ProQR Therapeutics N.V. (0PQ) stock gains from tech spendingWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Can ProQR Therapeutics N.V. stock hit analyst price targetsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Улправда
Is ProQR Therapeutics N.V. stock a safe haven assetJuly 2025 Catalysts & Weekly Breakout Watchlists - Улправда
Will ProQR Therapeutics N.V. stock maintain momentum in 20252025 Key Highlights & Community Consensus Picks - Улправда
Breakout Zone: Why ProQR Therapeutics N.V. (0PQ) stock stays undervaluedWeekly Stock Summary & Low Risk High Reward Trade Ideas - Улправда
Will ProQR Therapeutics N.V. (0PQ) stock justify high valuationTrade Analysis Summary & Long-Term Growth Portfolio Plans - Улправда
Bull Run: Is ProQR Therapeutics N.V. stock a buy in volatile marketsMarket Trend Review & Real-Time Volume Analysis - Улправда
Can ProQR Therapeutics N.V. stock sustain free cash flow growthJuly 2025 Earnings & Fast Moving Trade Plans - Улправда
Is ProQR Therapeutics N.V. (0PQ) stock nearing a technical breakoutTrade Volume Report & AI Powered Trade Plan Recommendations - DonanımHaber
ProQR Therapeutics N.V PRQR’s stock price falss traction on Friday - uspostnews.com
Ready to Jump After Recent Trade: ProQR Therapeutics N.V (PRQR) - setenews.com
Is ProQR Therapeutics NV 0PQ a good long term investmentDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Is ProQR Therapeutics N.V. (0PQ) stock a good hedge against inflationWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is ProQR Therapeutics N.V. (0PQ) stock a buy during volatile marketsCPI Data & Weekly Top Performers Watchlists - Newser
Will ProQR Therapeutics N.V. (0PQ) stock enhance shareholder value2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
ProQR Therapeutics N.V. (PRQR) 5.47% in After-hours: Gains Ahead of Healthcare Conference - Stocks Telegraph
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - setenews.com
Can ProQR Therapeutics N.V. (0PQ) stock surprise with quarterly results2025 Market Sentiment & Growth Focused Investment Plans - Newser
ProQR Therapeutics (PRQR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
How ProQR Therapeutics N.V. (0PQ) stock valuation compares with sectorQuarterly Portfolio Report & Safe Capital Growth Tips - Newser
Why ProQR Therapeutics N.V. (0PQ) stock is a strong buy callMarket Risk Report & Smart Allocation Stock Tips - Newser
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leaders2025 Historical Comparison & Weekly Setup with High ROI Potential - Newser
Is ProQR Therapeutics N.V. stock attractive for hedge funds2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
ProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025 - Quiver Quantitative
ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewswire Inc.
How ProQR Therapeutics N.V. stock benefits from global expansionQuarterly Investment Review & Comprehensive Market Scan Reports - BỘ NỘI VỤ
Taking on analysts’ expectations and winning: ProQR Therapeutics N.V (PRQR) - setenews.com
Activity Recap: Why ProQR Therapeutics N.V. stock is a value investor pickJuly 2025 Volume & Capital Protection Trade Alerts - moha.gov.vn
ProQR Therapeutics NV Stock Analysis and ForecastVWAP Trading Strategies & Market Trend Real-Time Reports - earlytimes.in
Whale Trades: Why ProQR Therapeutics N.V. stock is considered a top pick2025 Market WrapUp & Community Consensus Picks - moha.gov.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):